Filing Flows

Filing Flows › Companies › CervoMed › Cash flow

CervoMed cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$5.1M in Q3 2026 · −$26.6M over twelve months

Operating cash flow−$5.1M
Free cash flow−$5.1M

Analysis

In Q3 2026, CervoMed generated −$5.1M of operating cash flow. That is $1.4M more than in Q3 2025 (−$6.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$26.6M; the largest uses were operating cash flow ($26.6M); besides operations, cash came from other financing ($18.6M), other investing ($4.6M); the cash balance fell by $3.4M.

Operating cash flow was −$5.1M against net income of −$5.9M. The largest differences: payables +$930K, prepaid and other assets −$570K, accrued liabilities +$372K.

Free cash flow

CervoMed: free cash flow by quarterCervoMed: free cash flow by quarter−$8.1MQ4 2024−$3.9MQ1 2025−$6.5MQ2 2025−$6.5MQ3 2025−$6.6MQ4 2025−$8.0MQ1 2026−$6.9MQ2 2026−$5.1MQ3 2026
Operating cash flow less capital spending.
CervoMed: operating cash flow against capital spendingCervoMed: operating cash flow against capital spendingOperating cash flowCapital spending−$8.1M$0Q4 2024−$3.9M$0Q1 2025−$6.5M$0Q2 2025−$6.5M$0Q3 2025−$6.6M$0Q4 2025−$8.0M$0Q1 2026−$6.9M$0Q2 2026−$5.1M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$5.1M, Capital spending $0.

Capital allocation, year by year

CervoMed: where the cash came from (up) and went (down), by fiscal yearCervoMed: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesFY2021: Operating cash flow −$14.5MFY2021: Shares issued $31.1MFY2021: Asset sales $4K$31.1MFY2021FY2022: Operating cash flow −$2.6MFY2022: Shares issued $5K$5KFY2022FY2023: Operating cash flow −$7.4MFY2023: Shares issued $810K$810KFY2023FY2024: Operating cash flow −$16.5MFY2024: Shares issued $46.4M$46.4MFY2024FY2025: Operating cash flow −$23.4MFY2025
Over these 5 years operating cash flow totalled −$64.5M; the largest uses were operating cash flow ($64.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$19.6M
Debtnone
Net cash$19.6M
Cash runway9 months

CervoMed is burning cash: its operations consume cash, a free cash flow of −$26.6M a year at the current rate against $19.6M of cash and investments: a runway of about 9 months before any new financing.

Where the cash came from and went

CervoMed: sources (+) and uses (−) of cash, Q3 2026CervoMed: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)$16.4MOther investing−$11.0MOperating cash flow−$5.1MOther financing−$358K
CervoMed: sources (+) and uses (−) of cash, TTM to Q3 2026CervoMed: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$26.6MOther financing$18.6MOther investing$4.6MCash drawn (+) / kept (−)$3.4M

From profit to cash

CervoMed: net income to operating cash flow, Q3 2026CervoMed: net income to operating cash flow, Q3 2026Net income−$5.9MStock-based pay$307KPayables$930KAccrued liabilities$372KPrepaid and other assets−$570KOperating cash flow−$5.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$5.1M—$16.4M−$5.1M
Q2 2026−$6.9M—−$14.5M−$6.9M
Q1 2026−$8.0M$14K$294K−$8.0M
Q4 2025−$6.6M—$1.2M−$6.6M
Q3 2025−$6.5M—−$1.1M−$6.5M
Q2 2025−$6.5M—$2.2M−$6.5M
Q1 2025−$3.9M—−$1.5M−$3.9M
Q4 2024−$8.1M—−$1.3M−$8.1M

CervoMed: income statement and cash flow

CervoMed, Q4 2025: revenue $9K (-100% year over year). The chart follows the revenue to costs, profit and cash.

CervoMed: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.